MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma

Rajesh Pradhan; Gautam Singhvi; Sunil Kumar Dubey; Gaurav Gupta; Kamal Dua

doi:10.4155/fmc-2018-0468

MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma

Future Med Chem. 2019 Apr;11(8):793-795. doi: 10.4155/fmc-2018-0468. Epub 2019 Apr 17.

Authors

Rajesh Pradhan¹, Gautam Singhvi¹, Sunil Kumar Dubey¹, Gaurav Gupta², Kamal Dua^{3

4

5}

Affiliations

¹ Department of Pharmacy, Birla Institute of Technology & Science (BITS), Pilani 333031, India.
² School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur 302017, India.
³ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo NSW 2007, Australia.
⁴ School of Biomedical Sciences & Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia.
⁵ Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, NSW 2305, Australia.

PMID: 30994024
DOI: 10.4155/fmc-2018-0468

No abstract available

Keywords: EGFR; MAPK; MAPK pathway; RAS; apoptosis; cancer; cell proliferation; epidermal growth factor receptor; lung cancer; non-small-cell lung carcinoma.

Publication types

Editorial

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
ErbB Receptors / metabolism
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
MAP Kinase Signaling System / drug effects*
Molecular Targeted Therapy

Substances

Antineoplastic Agents
EGFR protein, human
ErbB Receptors